Baidu
map

Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study

Ritchlin, CT; Deodhar, A; Boehncke, WH; Soriano, ER; Kollmeier, AP; Xu, XL; Zazzetti, F; Shawi, M; Jiang, YS; Sheng, SH; Helliwell, PS

Ritchlin, CT (通讯作者)，Univ Rochester Med Ctr, Rochester, NY 14642 USA.

ACR OPEN RHEUMATOLOGY, 2023; 5 (3): 149

Abstract

ObjectiveTo evaluate efficacy and safety of the interleukin-23p19-subunit inhibitor, guselkumab, in DISCOVER-1 patients with active psoriatic arthriti......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

Baidu
map
Baidu
map
Baidu
map